Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 1
1947 3
1948 1
1949 2
1951 1
1952 3
1953 1
1954 3
1955 1
1956 1
1958 1
1959 1
1960 1
1961 1
1962 1
1963 1
1964 1
1965 1
1967 2
1969 1
1971 1
1974 1
1975 1
1992 1
1994 2
1995 2
1996 5
1997 4
1998 2
1999 5
2000 2
2001 2
2002 5
2003 6
2004 4
2005 5
2006 6
2007 1
2008 4
2009 9
2010 6
2011 8
2012 6
2013 6
2014 7
2015 5
2016 6
2017 11
2018 9
2019 19
2020 14
2021 15
2022 9
2023 9
2024 16
2025 18

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

239 results

Results by year

Filters applied: . Clear all
Page 1
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.
Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D, Sanchez-Guerrero J, Schwarting A, Merrill JT, Chatham WW, Stohl W, Ginzler EM, Hough DR, Zhong ZJ, Freimuth W, van Vollenhoven RF; BLISS-76 Study Group. Furie R, et al. Among authors: schwarting a. Arthritis Rheum. 2011 Dec;63(12):3918-30. doi: 10.1002/art.30613. Arthritis Rheum. 2011. PMID: 22127708 Free PMC article. Clinical Trial.
Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis.
Furie RA, Rovin BH, Garg JP, Santiago MB, Aroca-Martínez G, Zuta Santillán AE, Alvarez D, Navarro Sandoval C, Lila AM, Tumlin JA, Saxena A, Irazoque Palazuelos F, Raghu H, Yoo B, Hassan I, Martins E, Sehgal H, Kirchner P, Ross Terres J, Omachi TA, Schindler T, Pendergraft WF 3rd, Malvar A; REGENCY Trial Investigators. Furie RA, et al. N Engl J Med. 2025 Apr 17;392(15):1471-1483. doi: 10.1056/NEJMoa2410965. Epub 2025 Feb 7. N Engl J Med. 2025. PMID: 39927615 Clinical Trial.
Trial of Anifrolumab in Active Systemic Lupus Erythematosus.
Morand EF, Furie R, Tanaka Y, Bruce IN, Askanase AD, Richez C, Bae SC, Brohawn PZ, Pineda L, Berglind A, Tummala R; TULIP-2 Trial Investigators. Morand EF, et al. N Engl J Med. 2020 Jan 16;382(3):211-221. doi: 10.1056/NEJMoa1912196. Epub 2019 Dec 18. N Engl J Med. 2020. PMID: 31851795 Clinical Trial.
Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study.
Stohl W, Schwarting A, Okada M, Scheinberg M, Doria A, Hammer AE, Kleoudis C, Groark J, Bass D, Fox NL, Roth D, Gordon D. Stohl W, et al. Among authors: schwarting a. Arthritis Rheumatol. 2017 May;69(5):1016-1027. doi: 10.1002/art.40049. Epub 2017 Apr 7. Arthritis Rheumatol. 2017. PMID: 28118533 Free PMC article. Clinical Trial.
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.
Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, Agodoa L, Gaziano M, Kasiske B, Walker R, Massy ZA, Feldt-Rasmussen B, Krairittichai U, Ophascharoensuk V, Fellström B, Holdaas H, Tesar V, Wiecek A, Grobbee D, de Zeeuw D, Grönhagen-Riska C, Dasgupta T, Lewis D, Herrington W, Mafham M, Majoni W, Wallendszus K, Grimm R, Pedersen T, Tobert J, Armitage J, Baxter A, Bray C, Chen Y, Chen Z, Hill M, Knott C, Parish S, Simpson D, Sleight P, Young A, Collins R; SHARP Investigators. Baigent C, et al. Lancet. 2011 Jun 25;377(9784):2181-92. doi: 10.1016/S0140-6736(11)60739-3. Epub 2011 Jun 12. Lancet. 2011. PMID: 21663949 Free PMC article. Clinical Trial.
Disease-modifying therapies in systemic lupus erythematosus for extrarenal manifestations.
Askanase AD, Furie RA, Dall'Era M, Bomback AS, Schwarting A, Zhao MH, Bruce IN, Khamashta M, Rubin B, Carroll A, Daniels M, Levy RA, van Vollenhoven R, Urowitz MB. Askanase AD, et al. Among authors: schwarting a. Lupus Sci Med. 2024 May 22;11(1):e001124. doi: 10.1136/lupus-2023-001124. Lupus Sci Med. 2024. PMID: 38777595 Free PMC article. Review.
Autoantibodies against the chemokine receptor 3 predict cardiovascular risk.
Müller FS, Aherrahrou Z, Grasshoff H, Heidorn MW, Humrich JY, Johanson L, Aherrahrou R, Reinberger T, Schulz A, Ten Cate V, Robles AP, Koeck T, Rapp S, Lange T, Brachaczek L, Luebber F, Erdmann J, Heidecke H, Schulze-Forster K, Dechend R, Lackner KJ, Pfeiffer N, Ghaemi Kerahrodi J, Tüscher O, Schwarting A, Strauch K, Münzel T, Prochaska JH, Riemekasten G, Wild PS. Müller FS, et al. Among authors: schwarting a. Eur Heart J. 2023 Dec 14;44(47):4935-4949. doi: 10.1093/eurheartj/ehad666. Eur Heart J. 2023. PMID: 37941454 Free PMC article.
Pulmonary arterial hypertension in systemic lupus erythematosus: identification of risk factors and haemodynamics characteristics in a multicentre retrospective cohort.
Marasco E, Düsing C, Keymel S, Bortoluzzi A, Bracaglia C, Canuet M, Cavazzana I, Chehab G, Codullo V, Fischer R, Franceschini F, Fredi M, Ghio S, Keller L, Meyer A, Montecucco C, Richter J, Riou M, Sahin S, Sander O, Schwarting A, Scirè CA, Silvagni E, Triantafyllias K, Zanframundo G, Cavagna L, Schneider M. Marasco E, et al. Among authors: schwarting a. Lupus Sci Med. 2025 Jun 12;12(1):e001471. doi: 10.1136/lupus-2024-001471. Lupus Sci Med. 2025. PMID: 40514051 Free PMC article.
239 results